Bicara therapeutics reports second quarter 2025 financial results and provides business update

Updated data from phase 1/1b trial presented at 2025 asco annual meeting demonstrated deep and durable responses in 1l hpv-negative r/m hnscc

BCAX Ratings Summary

BCAX Quant Ranking